Table 2.

Select ongoing clinical trials of DLL3-targeting therapies

Treatment	Study ID	Tumor type	Target enrollment, n	Phase (status)
Tarlatamab	NCT03319940	SCLC	382	Phase I (recruiting)
	NCT04702737	NEPC	60	Phase I (recruiting)
	NCT04885998	SCLC	50	Phase I (recruiting)
	NCT05060016	SCLC	160	Phase II (recruiting)
BI 764532	NCT04429087	SCLC and other NEN	110	Phase I (recruiting)
HPN328	NCT04471727	SCLC and other high-grade NET	57	Phase I/II (recruiting)

NET, neuroendocrine tumor; NEPC, neuroendocrine prostate cancer; SCLC, small-cell lung cancer.